Keto diet for disease management

By | August 28, 2020

keto diet for disease management

Although some of the evidence is from case studies and animal research, results from human controlled studies are also promising. Anti-seizure medications are effective for some people with epilepsy. However, others don’t respond to the drugs or can’t tolerate their side effects. Of all the conditions that may benefit from a ketogenic diet, epilepsy has by far the most evidence supporting it. In fact, there are several dozen studies on the topic. This is also known as a ketogenic diet because it provides 4 times as much fat as protein and carbs combined 1, 2, 3. The modified Atkins diet MAD is based on a considerably less restrictive ratio of fat to protein and carbs. It has been shown to be equally effective for seizure control in most adults and children older than two years of age 4, 5, 6, 7, 8.

The goal of this paper is to review current literature on nutritional ketosis within the context of weight management and metabolic syndrome—namely insulin resistance, lipid profile and cardiovascular disease risk, and development of non-alcoholic fatty liver disease. We provide background on the mechanism of ketogenesis and describe nutritional ketosis. Nutritional ketosis has been found to improve metabolic and inflammatory markers, including lipids, HbA1c, high-sensitivity CRP, fasting insulin and glucose levels, and aid in weight management. We discuss these findings and elaborate on potential mechanisms of ketones for promoting weight loss, decreasing hunger, and increasing satiety. Humans have evolved with the capacity for metabolic flexibility and the ability to use ketones for fuel.

Disease keto diet management for

I think monosaturated fats should be emphasized — such as is found in peanut butter and olive oil. Besides a positive dosease on weight loss, studies have shown that low-carbohydrate ketogenic diets also reduce serum triglycerides dramatically. Recent studies also suggest that ketogenic diets may, in fact, induce hepatic insulin resistance February BMJh